| __timestamp | BioCryst Pharmaceuticals, Inc. | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 50829000 |
| Thursday, January 1, 2015 | 13047000 | 57305000 |
| Friday, January 1, 2016 | 11253000 | 116145000 |
| Sunday, January 1, 2017 | 13933000 | 159362000 |
| Monday, January 1, 2018 | 29514000 | 206366000 |
| Tuesday, January 1, 2019 | 37121000 | 228244000 |
| Wednesday, January 1, 2020 | 67929000 | 293355000 |
| Friday, January 1, 2021 | 118818000 | 401715000 |
| Saturday, January 1, 2022 | 159371000 | 459856000 |
| Sunday, January 1, 2023 | 213894000 | 542705000 |
| Monday, January 1, 2024 | 492128000 |
Unlocking the unknown
In the competitive world of biotechnology, managing costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Exelixis, Inc. and BioCryst Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Exelixis consistently outspent BioCryst, with its SG&A expenses growing by over 900%, from approximately $51 million in 2014 to $543 million in 2023. In contrast, BioCryst's expenses increased by nearly 280%, from around $7 million to $214 million. This disparity highlights Exelixis's aggressive expansion strategy, possibly reflecting its larger scale and broader market reach. Meanwhile, BioCryst's more conservative spending may indicate a focus on niche markets or a more cautious growth approach. Understanding these financial strategies provides valuable insights into each company's operational priorities and market positioning.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Exelixis, Inc.
Pfizer Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or BioCryst Pharmaceuticals, Inc.
Exelixis, Inc. or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and HUTCHMED (China) Limited
Comparing SG&A Expenses: Exelixis, Inc. vs Novavax, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and MiMedx Group, Inc.
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.
Mesoblast Limited and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared